Gene therapies now account for most ATMP clinical trials, with a balanced distribution between in vivo and ex vivo approaches. Oncology remains dominant (38%), but there is increasing activity in metabolic (13%) and hematological (10%) areas.
Notably, in December 2023, the FDA approved Casgevy — the first CRISPR-based therapy — for sickle cell disease and beta-thalassemia. By Q3 2024, over half of newly initiated gene therapy trials targeted non-oncology indications.
Axcellant has extensive experience in this space, supporting clinical programs involving CAR-T cells, cancer vaccines, and stem cells. We help biotech teams manage the regulatory, logistical, and operational complexity behind these groundbreaking therapies.
Discover our capabilities in ATMP trial delivery.
A recent publication in npj Digital Medicine explored the use of AI-generated radiology reports — and the results are worth…
The Axcellant team recently traveled to New York to meet with research partners and clinical collaborators from across the U.S.…
What Are Nuclear Medicine Procedures and How Are They Used in Clinical Trials? Nuclear medicine procedures (NMPs) are diagnostic and/or…
Copyright @ 2025 Axcellant